Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
HLS Therapeutics Inc ( (TSE:HLS) ) has provided an announcement.
HLS Therapeutics reported fiscal 2025 revenue of $55.5 million, with Adjusted EBITDA rising 18% to $19.6 million and cash from operations more than doubling to $17.1 million. The company cut operating expenses, reduced long-term debt by 26%, and lowered annual interest costs by 43% through a new credit facility.
Canadian product sales grew modestly in local currency, while U.S. Clozaril declines slowed, aided by a specialty pharmacy program, and Vascepa turned profitable for the full year. HLS expanded its cardiovascular portfolio by in-licensing NILEMDO and NEXLIZET for Canada, with NILEMDO now approved and available, and signalled that near-term guidance reflects launch investments ahead of expected stronger growth from these products after 2026.
Management projects 2026 revenue of $56 million to $60 million and Adjusted EBITDA of $18.5 million to $21 million, anticipating mid-single-digit top-line growth and roughly flat earnings due to NILEMDO launch costs. With a strengthened balance sheet and additional financial flexibility, the company plans to leverage its stable base business and new cardiovascular assets to drive sustained profitable growth and potentially expand its portfolio further.
The most recent analyst rating on (TSE:HLS) stock is a Hold with a C$4.75 price target. To see the full list of analyst forecasts on HLS Therapeutics Inc stock, see the TSE:HLS Stock Forecast page.
Spark’s Take on TSE:HLS Stock
According to Spark, TipRanks’ AI Analyst, TSE:HLS is a Neutral.
The score is held back primarily by ongoing net losses and soft revenue trends despite strong gross margins, while positive and improving cash generation and manageable leverage provide support. Technically, indicators point to weak momentum, and valuation remains constrained by negative earnings; the latest earnings call adds a modest positive tilt due to EBITDA growth and debt reduction but is tempered by revenue and product-growth headwinds.
To see Spark’s full report on TSE:HLS stock, click here.
More about HLS Therapeutics Inc
HLS Therapeutics Inc. is a Toronto-based pharmaceutical company focused on treatments for psychiatric disorders and cardiovascular disease. Its portfolio includes the antipsychotic Clozaril and heart drug Vascepa, and it is expanding its cardiovascular franchise in the Canadian market with newly in-licensed products NILEMDO and NEXLIZET.
Average Trading Volume: 10,609
Technical Sentiment Signal: Sell
Current Market Cap: C$133.5M
For a thorough assessment of HLS stock, go to TipRanks’ Stock Analysis page.